Abstract | BACKGROUND: METHODS: We enrolled women (>16 years of age) with diabetes, bacteriuria (> or =105 colony-forming units of an organism per milliliter in cultures of two consecutive urine specimens), and no urinary symptoms; 50 were randomly assigned to receive placebo and 55 to receive antimicrobial therapy. For the first six weeks, which included the initial course of treatment, the study was placebo-controlled and double-blind. Subsequently, the women were screened for bacteriuria every three months for up to three years; antimicrobial therapy was provided to women in the antimicrobial-therapy group who had asymptomatic bacteriuria. RESULTS: Four weeks after the end of the initial course of therapy, 78 percent of placebo recipients had bacteriuria, as compared with 20 percent of women who received antimicrobial agents (P<0.001). During a mean follow-up of 27 months, 20 of 50 women in the placebo group (40 percent) and 23 of 55 women in the antimicrobial-therapy group (42 percent) had at least one episode of symptomatic urinary tract infection. The time to a first symptomatic episode was similar in the placebo group and the antimicrobial-therapy group (P=0.67 by the log-rank test), as were the (+/-SD) rates of any symptomatic urinary tract infection (1.10+/-0.17 and 0.93+/-0.14 per 1000 days of follow-up, respectively; relative risk, 1.19; 95 percent confidence interval, 0.28 to 1.81), pyelonephritis (0.28+/-0.08 and 0.13+/-0.05 per 1000 days of follow-up; relative risk, 2.13; 95 percent confidence interval, 0.81 to 5.62), and hospitalization for urinary tract infection (0.10+/-0.36 and 0.06+/-0.22 per 1000 days of follow-up; relative risk, 1.93; 95 percent confidence interval, 0.47 to 7.89). The women in the antimicrobial-therapy group had almost five times as many days of antibiotic use for urinary tract infection as did the women in the placebo group (158.2+/-1.7 vs. 33.7+/-0.91 per 1000 days of follow-up; relative risk, 0.21; 95 percent confidence interval, 0.20 to 0.22). CONCLUSIONS: Treatment of asymptomatic bacteriuria in women with diabetes does not appear to reduce complications. Diabetes itself should not be an indication for screening for or treatment of asymptomatic bacteriuria.
|
Authors | Godfrey K M Harding, George G Zhanel, Lindsay E Nicolle, Mary Cheang, Manitoba Diabetes Urinary Tract Infection Study Group |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 347
Issue 20
Pg. 1576-83
(Nov 14 2002)
ISSN: 1533-4406 [Electronic] United States |
PMID | 12432044
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2002 Massachusetts Medical Society |
Chemical References |
- Anti-Infective Agents, Urinary
- Drug Combinations
- Sulfamethizole
- trimethoprim sulfamethizole
- Trimethoprim
|
Topics |
- Anti-Infective Agents, Urinary
(therapeutic use)
- Bacteriuria
(complications, drug therapy)
- Cystitis
(etiology, prevention & control)
- Diabetes Complications
- Double-Blind Method
- Drug Combinations
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Prospective Studies
- Pyelonephritis
(etiology, prevention & control)
- Sulfamethizole
(therapeutic use)
- Trimethoprim
(therapeutic use)
- Urinary Tract Infections
(etiology, prevention & control)
|